Lung Cancer

The FDA approved encorafenib plus binimetinib for treatment of certain patients with non-small cell lung cancer.

Pembrolizumab as neoadjuvant and adjuvant therapy significantly extended OS among adults with resectable stage II, IIIA or IIIB non-small cell lung cancer, according to the agent’s manufacturer.

Information AI-powered chatbots provided related to search queries on the most common cancer types generally produced accurate information with poor actionability, study results published in JAMA Oncology showed.

HONOLULU — A model that incorporates demographic and smoking history data has identified regions populated with individuals eligible for lung cancer screening, according to study results presented at the CHEST Annual Meeting.

A novel liquid biopsy test can help determine whether patients with oligometastatic non-small cell lung cancer will benefit more from targeted, high-dose radiation instead of drug-based therapy, according to study results.

An FDA advisory committee voted 10-2 that the results of a confirmatory trial for the targeted lung cancer drug sotorasib cannot be interpreted reliably.

Takeda will work with the FDA toward voluntary withdrawal of its lung cancer therapy mobocertinib from the U.S. market, according to a company press release.

Amivantamab plus lazertinib improved PFS compared with osimertinib as first-line therapy in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

New diagnoses for six of the most common cancer types sharply declined in the U.S. in early 2020 — along with the volume of pathology reports — largely due to the start of the COVID-19 pandemic, according to data released by NCI.

The addition of nivolumab to neoadjuvant chemotherapy followed by adjuvant nivolumab extended EFS among patients with resectable non-small cell lung cancer, according to the agent’s manufacturer.